Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare disease-free survival (DFS) of patients
with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus
moxifloxacin or placebo.